# Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment

> **NCT05552859** · PHASE4 · TERMINATED · sponsor: **Sanofi** · enrollment: 62 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Renal Impairment

## Interventions

- **DRUG:** Insulin glargine 300 U/mL
- **DRUG:** Insulin degludec 100 U/mL

## Key facts

- **NCT ID:** NCT05552859
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-05
- **Primary completion:** 2023-07-28
- **Final completion:** 2023-08-04
- **Target enrollment:** 62 (ACTUAL)
- **Why stopped:** Sponsor decision to cancel trial due to poor recruitment/ severe recruitment delay and not related to safety concern.
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05552859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05552859, "Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05552859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*